H2020Индивидуална стипендия2019–2022

ReSurface · A combined developmental cell biology and tissue engineering approach to repair the articular surface of synovial joints

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период: 2019-08-01 → 2022-11-30
Финансиране от ЕС: 248 063 €
Участници: 2
Схема: MSCA-IF

Линиите свързват координатора с партньорите.

Накратко на български

Хрущялите в ставите се изследват чрез създаване на човешки модели в лаборатория, за да се разбере как стъбновите клетки се превръщат в хрущялни. Това помага за откриването на нови мишени за лекарства, които да забавят развитието на остеоартрита.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

A combined developmental cell biology and tissue engineering approach to repair the articular surface of synovial joints

Articular cartilage lines our joints, allowing for frictionless joint movement. If damaged, the resident cells, articular chondrocytes (ACs), are unable to repair. Instead, a progressive degradation of the cartilage begins, eventually developing into osteoarthritis which affects approximately 10-12% of the adult population and causing pain, stiffness, and inflammation and thus severely impacting quality of life. Early treatment of articular cartilage damage may correct disease progression; however suitable treatments remain inadequate, due to gaps in our knowledge of how this type of cartilage forms from stem cells prenatally, and how it is maintained postnatally. Therefore, the objective of ReSurface was to develop methods to generate and study articular cartilage in the lab, carefully observing how articular cartilage forms and challenge this process with different chemicals to tease out important factors responsible for maintenance of healthy cartilage, and finally design a minimally-invasive device capable of safely delivering therapy to damaged cartilage. Results from ReSurface have pushed the frontiers of human cartilage biology by developing an in vitro model of human articular cartilage development. Previously, cartilage biology was studied using animal models so for the first time, our model allows us to probe early human cartilage development which will have impact across developmental biology and also cartilage disease research. We have performed in-depth analysis of human stem cells as they become articular chondrocytes and continued to study cell behavior over long-term experiments focusing on maintenance of healthy cartilage. As well as generating new insights into human cartilage development, we have identified novel drug targets that could mitigate osteoarthritis progression and designed a minimally invasive delivery device that can carry cells or drugs to sites of cartilage damage. Taken together, ReSurface has formed the basis of series of new therapies that could halt progression of osteoarthritis and remove the need for joint replacement surgery in the near future.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Repair of articular cartilage defects remains a significant clinical challenge due to gaps in our knowledge of articular cartilage development and maintenance in adulthood. This creates a lack of consensus on the ideal cell source for cell-based repair strategies and suitable methods of delivery. The overall goal of ReSurface is to develop a cell therapy platform for articular cartilage defect repair. This will be achieved by unravelling the molecular mechanisms controlling articular cartilage cell development and maintenance, generation of a panel of molecular parameters defining populations of cells that are safe and suitable for articular cartilage repair, and development of a minimally invasive method to deliver cells to the defect site. This project is highly multidisciplinary and intersectoral combining fundamental developmental and molecular cell biology with advanced engineering techniques and including significant industry and clinical collaboration throughout. This fellowship will have an outgoing phase at Dr April Craft’s Lab at Boston Children’s Hospital (BCH), affiliated with Harvard Medical School (HMS) and the Harvard Stem Cell Institute (HSCI), and a return phase to Prof Garry Duffy’s Lab at the National University of Ireland, Galway (NUIG) which is part of the Science Foundation Ireland funded Centre for Research in Medical Devices (CÚRAM). Clinical collaborators will include BCH, Brigham and Women’s Hospital, Boston, University College Hospital Galway (UCHG) and the Regenerative Medicine Institute (REMEDI) at NUIG while industry collaborators include Boston Scientific Limited (BSL). Having recently completed my PhD in biomaterials development, this project will diversify my professional competencies through advanced training with intersectoral and international collaborations and provide me with the scientific and transferable skills required for my transition to an independent scientist role.

Оригинален текст от CORDIS (на английски).

Участници

UNIVERSITY OF GALWAY · GalwayКоординаторИрландия
CHILDREN'S HOSPITAL CORPORATION · BostonСъединени щати